Table 1

Baseline characteristics of patients in the two analytic cohorts. GOG-99 only indicates patients meeting only the GOG-99 high–intermediate risk criteria; PORTEC-1 indicates patients meeting only the PORTEC-1 high–intermediate risk criteria.

GOG-99 only
(n=11,207)
No. (%)
PORTEC-1 only
(n=5,920)
No. (%)
Sociodemographic factors
Year of diagnosis
 20101589 (14.2)804 (13.6)
 20111653 (14.7)883 (14.9)
 20121870 (16.7)964 (16.3)
 20131950 (17.4)1004 (17.0)
 20142040 (18.2)1128 (19.1)
 20152105 (18.8)1137 (19.2)
 Age
 ≤60 years3755 (33.5)0 (0.0)
 >60 years7452 (66.5)5920 (100.0)
Charlson-Deyo co-morbidity score
 08092 (72.2)4332 (73.2)
 12473 (22.1)1275 (21.5)
 ≥2642 (5.7)313 (5.3)
Race/ethnicity
 Non-black10266 (91.6)5062 (85.5)
 Black862 (7.7)784 (13.2)
 Unknown79 (0.7)74 (1.3)
Insurance status
 Government7029 (62.7)3173 (53.6)
 Private3807 (34.0)2517 (42.5)
 Uninsured265 (2.4)156 (2.6)
 Unknown106 (0.9)74 (1.3)
Facility type
 Academic6288 (56.1)3335 (56.3)
 Community/comprehensive community4901 (43.7)2585 (43.7)
 Unknown18 (0.2)0 (0.0)
Facility location
 Midwest3004 (26.8)1608 (27.2)
 Northeast5201 (46.4)2780 (47.0)
 South1405 (12.5)656 (11.1)
 West1579 (14.1)876 (14.8)
 Unknown18 (0.2)0 (0.0)
Pathological factors
FIGO stage
 IA8733 (77.9)3611 (61.0)
 IB2474 (22.1)2309 (39.0)
Lymphovascular invasion
 No7138 (63.7)5920 (100.0)
 Yes4069 (36.3)0 (0.0)
Histologic grade
 Grade 1721 (6.4)2309 (39.0)
 Grade 210007 (89.3)0 (0.0)
 Grade 3479 (4.3)3611 (61.0)
Treatment factors
Received radiation therapy
 No7414 (66.2)3382 (57.1)
 Yes3793 (33.8)2538 (42.9)
Radiation therapy modality
 Brachytherapy alone2981 (26.6)2115 (35.7)
 External beam therapy alone532 (4.7)282 (4.8)
 External beam and brachytherapy280 (2.5)141 (2.4)
 No radiation7414 (66.2)3382 (57.1)
Received chemotherapy
 No10302 (91.9)4340 (73.3)
 Yes905 (8.1)1580 (26.7)
Received lymph node dissection
 No2376 (21.2)995 (16.8)
 Yes8820 (78.7)4916 (83.0)
 Unknown11 (0.1)9 (0.2)